# Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

> **NCT00386425** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 486 (actual)

## Conditions studied

- Severe Sepsis

## Interventions

- **DRUG:** Drotrecogin alfa (activated)

## Key facts

- **NCT ID:** NCT00386425
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 486 (ACTUAL)
- **Last updated:** 2010-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386425, "Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00386425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*